SCM
VYNT

Stonepine Capital Management’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Stonepine Capital Management’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,096
Closed -$639K – 30
2018
Q3 		$639K Sell
4,096
-5,181
-56% -$767K 0.37% 28
2018
Q2 		$1.24M Sell
9,277
-2,541
-22% -$384K 0.75% 21
2018
Q1 		$2.92M Sell
11,818
-89
-0.7% -$25.1K 1.57% 17
2017
Q4 		$3.3M Buy
+11,907
New +$4.54M 1.98% 16

Other funds holding VYNT

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $169M AUM 12.21% 1-Year Est. Return
DM
Diker Management New York $130M AUM 97.77% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Stonepine Capital Management's VYNT Position: Q4 2018 in Review

Stonepine Capital Management sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2018, closing a stake of 4,096 shares — an estimated $639K sold.

Stonepine Capital Management first reported a position in VYNT in Q4 2017 and held it in 4 quarters. The position peaked at $3.3M in Q4 2017. 27 funds tracked by Wall St. Rank hold VYNT as of Q4 2018.

  • Stonepine Capital Management reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Stonepine Capital Management sold 4,096 Vyant Bio, Inc. Common Stock shares in Q4 2018, an estimated $639K.
  • Stonepine Capital Management first reported a position in Vyant Bio, Inc. Common Stock in Q4 2017 and held it in 4 quarters.
  • Stonepine Capital Management's Vyant Bio, Inc. Common Stock position peaked at $3.3M in Q4 2017.
  • 27 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2018.

Based on Stonepine Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.